2 protocols meet the specified criteria
- OCR16600
A multicenter, 18-week open label safety and efficacy trial of Dalfampridine in primary lateral sclerosis
- OCR17045
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis